STOCK TITAN

Cartesian Therapeutics (RNAC) Stock News, Aug 2025-Jan 2026

RNAC NASDAQ

Cartesian Therapeutics, Inc. reports news on its late clinical-stage biotechnology work in mRNA-engineered cell therapy for autoimmune diseases. The company's lead asset, Descartes-08, is an autologous BCMA-targeting CAR-T candidate being developed for generalized myasthenia gravis, myositis indications such as dermatomyositis and antisynthetase syndrome, and pediatric autoimmune diseases including juvenile dermatomyositis.

Recurring updates cover clinical program progress across AURORA, TRITON and HELIOS, FDA designations for Descartes-08, financial results and cash runway commentary, corporate presentations and investor conference participation. News also includes Nasdaq employment inducement grants, equity incentive plan activity, and board or committee changes tied to the company's public-company governance.

Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC) announced inducement stock option awards to two new employees granted on January 2, 2026. The company issued options to purchase an aggregate of 7,350 shares at an exercise price of $6.76, equal to the Nasdaq closing price on the grant date.

The options were granted under the company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan, approved by the board, vest 25% on January 2, 2027 and then in 36 equal monthly installments, fully vesting on January 2, 2030, and have a ten-year term. Grants were made under Rule 5635(c)(4) of the Nasdaq Listing Rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
-
Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC) announced the appointment of Adrian Bot, M.D., Ph.D. to its Board of Directors effective Dec. 18, 2025. Dr. Bot brings three decades of R&D experience in immune, cell, gene therapy and nanomedicines and will serve on the Board's Science and Technology Committee.

His background includes senior R&D roles at Capstan, Kite/Gilead, MannKind and Alliance Pharma, involvement with first-in-class CAR T development, and leadership in RNA-based precision medicines; he has co-authored >200 peer-reviewed works.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.90%
Tags
management
-
Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC) reported initial Phase 2 results for Descartes-08 in SLE showing a 100% LLDAS response at Month 3 among participants who reached that visit (n=3) and 2 of 3 DORIS remissions. Descartes-08 was well tolerated in the outpatient setting with no CRS or ICANS reported and statistically significant reductions (p<0.01) in several proinflammatory cytokines and plasmacytoid dendritic cells. The company will pause further SLE enrollment to prioritize Phase 3 myasthenia gravis and a planned seamless adaptive Phase 2-to-pivotal trial in myositis expected to start in 1H 2026, with an IND filing planned by end of 2025. Cash runway is expected to support operations through mid-2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC) reported Q3 2025 results and clinical updates on Nov 6, 2025. The company reported $145.1 million in cash, cash equivalents and restricted cash as of Sept 30, 2025, which it expects will support operations into mid-2027, including completion of the Phase 3 AURORA trial.

Clinical highlights: enrollment is on track in the randomized Phase 3 AURORA trial of Descartes-08 in acetylcholine receptor antibody-positive myasthenia gravis (~100 participants; primary endpoint: ≥3-point MG-ADL improvement at Month 4), preliminary Phase 2 Descartes-08 SLE data expected by year-end, and a pediatric basket Phase 2 trial initiation expected by year-end; FDA granted Rare Pediatric Disease Designation for Descartes-08 in juvenile dermatomyositis. Descartes-15 Phase 1 in multiple myeloma remains ongoing.

Financials: R&D $13.8M, G&A $7.7M for Q3 2025; net loss $35.9M, or $1.38 per share, vs. net loss $24.2M, or $1.13 per share in Q3 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
-
Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC) announced inducement stock-option awards to two new employees dated Oct 27, 2025 and Oct 29, 2025. One option covers 50,000 shares at an exercise price of $8.85 (closing price on Oct 27, 2025); the other covers 2,650 shares at an exercise price of $8.20 (closing price on Oct 29, 2025).

Both grants were approved by the board under the Amended and Restated 2018 Employment Inducement Incentive Award Plan, vest 25% after one year then in three equal annual installments (fully vested in 2029), and carry a 10-year term. Grants were made under Nasdaq Rule 5635(c)(4) as inducements to employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.10%
Tags
none
-
Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC) announced that Carsten Brunn, Ph.D., currently President and CEO, was named Chairman of the Board effective October 29, 2025.

Dr. Brunn succeeds Carrie S. Cox, who is stepping down to focus on other responsibilities, including a recent appointment as Executive Chair of another publicly traded company. In connection with the change, Patrick Zenner, M.B.A. was named Lead Independent Director.

The company highlighted progress advancing Descartes-08 toward its first planned regulatory submission and referenced the board leadership transition as part of its corporate governance updates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.10%
Tags
management
Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC) announced an employment inducement grant for one new employee on Oct 2, 2025. The company issued an option for 9,700 shares with an exercise price of $10.34 (Nasdaq close on grant date). The option was approved by the board and granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement award.

The option vests 25% on Oct 2, 2026, then in three equal annual installments, becoming fully vested on Oct 2, 2029, and carries a 10-year term.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
none
-
Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on cell therapy for autoimmune diseases, has announced its participation in three major healthcare investor conferences in September 2025.

The company will participate in the Cantor Global Healthcare Conference on September 4, the Morgan Stanley Healthcare Conference on September 9, and the H.C. Wainwright Global Investment Conference on September 10. All presentations will be available via webcast on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
conferences
-
Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 2025 financial results and provided key pipeline updates. The company has initiated its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis, with the first participant enrolled in May 2025. The trial will evaluate the therapy versus placebo in approximately 100 participants.

The company maintains a strong financial position with $162.1 million in cash and equivalents as of June 30, 2025, expected to fund operations into mid-2027. Q2 2025 saw a net income of $15.9 million ($0.51 per share). Cartesian anticipates preliminary data from its Phase 2 trial of Descartes-08 in systemic lupus erythematosus and plans to initiate a pediatric basket trial in select autoimmune indications in 2H25.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on cell therapy for autoimmune diseases, has granted employment inducement awards to two new employees. The company issued stock options to purchase 5,750 shares at an exercise price of $12.48 per share on August 4, 2025.

The options were granted under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan with a four-year vesting schedule. The initial 25% vests on August 4, 2026, followed by three equal annual installments, becoming fully vested by August 4, 2029. The options have a ten-year term and were granted under Nasdaq Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.21%
Tags
none

FAQ

What is the current stock price of Cartesian Therapeutics (RNAC)?

Cartesian Therapeutics (RNAC) last closed at $6.08.

What is the market cap of Cartesian Therapeutics (RNAC)?

The market cap of Cartesian Therapeutics (RNAC) is approximately $185.5M.